Europe's drug regulator just made it easier to reverse an opioid overdose. The EMA's CHMP recommended reclassifying Nyxoid (naloxone) nasal spray as an over-the-counter medication, allowing bystanders — no medical training required — to administer it during an emergency. The needle-free spray is approved for adults and adolescents 14 and older and works by rapidly blocking opioid receptors to reverse life-threatening respiratory suppression.
Europe's drug regulator just made it easier to reverse an opioid overdose.
At its October 2026 meeting, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended reclassifying Nyxoid — a naloxone nasal spray made by Mundipharma — as an over-the-counter (OTC) medication. The move is designed to enable faster, community-level responses to opioid overdoses caused by substances like heroin or morphine, without waiting for medical professionals to arrive. The needle-free format also eliminates needle-stick injury risks for bystanders.
Naloxone works by rapidly blocking opioid receptors, reversing the dangerous respiratory suppression that can come with opioid toxicity. It has been a cornerstone of overdose treatment since the 1970s. Nyxoid is approved for adults and adolescents aged 14 and older, and the European Commission first granted it EU-wide marketing authorization back in November 2017.
By the Numbers:
Why it matters: Making naloxone available OTC removes a critical barrier to overdose survival — time. When every second counts, empowering bystanders to act immediately could save lives across Europe.
